Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT) (BESTFIT)

This study has been completed.
Information provided by (Responsible Party):
Tonix Pharmaceuticals, Inc. Identifier:
First received: July 12, 2013
Last updated: November 5, 2015
Last verified: November 2015
TNX-102 capsules [formerly known as very low dose (VLD) cyclobenzaprine] at bedtime has shown promise as a treatment of fibromyalgia, but the drug required new formulation technology for bedtime use. The present trial is designed to assess the safety and efficacy of TNX-102 SL 2.8 mg tablets, taken daily at bedtime over 12 weeks to treat fibromyalgia.

Condition Intervention Phase
Primary Fibromyalgia
Drug: TNX-102 SL 2.8mg Tablets
Drug: Placebo
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2b, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Tablets Taken at Bedtime in Patients With Fibromyalgia

Resource links provided by NLM:

Further study details as provided by Tonix Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • Average perceived pain [ Time Frame: Weeks 12 mean change of perceived average pain intensity from baseline ] [ Designated as safety issue: No ]
    To evaluate the efficacy of TNX-102 (low-dose cyclobenzaprine) sublingual (SL) tablets taken at bedtime over 12 weeks of treatment using an 11-point (0-10) numerical rating scale (NRS) to assess average daily pain over 24 hours.

Secondary Outcome Measures:
  • Patient's Global Impression of Change [ Time Frame: Weeks 2, 4, 8 and 12 or early termination ] [ Designated as safety issue: No ]
  • Fibromyalgia Impact Questionnaire [ Time Frame: Baseline and weeks 2, 4, 8 and 12 ] [ Designated as safety issue: No ]
  • Patient pain improvement response rate [ Time Frame: Weekly ] [ Designated as safety issue: No ]
  • SF-36 Physical Component score [ Time Frame: Baseline and weeks 4, 8 and 12 ] [ Designated as safety issue: No ]
  • Safety of TNX-102 SL Tablets [ Time Frame: Continuously throughout the treatment period (total duration: about 3 months) ] [ Designated as safety issue: Yes ]
    Every adverse events occurring during the study period will be reported.

Enrollment: 205
Study Start Date: September 2013
Study Completion Date: November 2015
Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: TNX-102 SL 2.8 mg Tablets
1 x TNX-102 SL 2.8mg Tablet taken sublingually each day at bedtime for 12 weeks.
Drug: TNX-102 SL 2.8mg Tablets
Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
Other Name: Low dose cyclobenzaprine sublingual tablets
Placebo Comparator: Placebo
1 x Placebo Tablet taken sublingually each day at bedtime for 12 weeks.
Drug: Placebo
Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
Other Name: Placebo sublingual tablets


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of Primary Fibromyalgia (ACR criteria)
  • Male or female 18-65 years old
  • For patients with major depressive disorders only: clinically stable, no suicidal risk and stable anti-depressent therapy
  • Willing and able to withdraw specific therapies (ask PI)
  • Medically acceptable form of contraception (female only)
  • Signed informed consent

Exclusion Criteria:

  • Arthritis, lupus and other systemic auto-immune diseases
  • Regional or persistent pain that could interfere with assessment of fibromyalgia pain
  • Bipolar and psychotic disorders
  • Increase risk of suicide
  • Significant clinical (cardiac, systemic infection, systemic corticosteroid requirement, drug/alcohol abuse) or laboratory abnormalities.
  • Unability to wash-out specific medications (ask PI)
  • Known hypersensitivity to cyclobenzaprine
  • Others: seizure disorders, sleep apnea, CPAP use, BMI>40
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01903265

United States, California
107 Scripps Drive
Sacramento, California, United States, 95825
United States, Colorado
Radiant Research, Inc.
Denver, Colorado, United States, 80239
United States, Florida
16176 Cortez Boulevard
Brooksville, Florida, United States, 34601
100 West Gore Street
Orlando, Florida, United States, 32806
United States, Illinois
3401 North Central Avenue
Chicago, Illinois, United States, 60634
United States, Maryland
71 Thomas Johnson Drive
Frederick, Maryland, United States, 21702
United States, Massachusetts
370 Faunce Corner Road
North Dartmouth, Massachusetts, United States, 02747
Clinical Pharmacology Study Group
Worcester, Massachusetts, United States, 01605
United States, Mississippi
CRC of Jackson, LLC
Jackson, Mississippi, United States, 39202
United States, Ohio
University of Cincinnati College of Medicine
Cincinnati, Ohio, United States, 45219
1275 Olentangy River Road
Columbus, Ohio, United States, 43212
18660 Bagley Road
Middleburg Heights, Ohio, United States, 44130
United States, Pennsylvania
1001 South Market Street
Mechanicsburg, Pennsylvania, United States, 17055
United States, South Carolina
322 Memorial Drive
Greer, South Carolina, United States, 29650
United States, Utah
1002 E. South Temple
Salt Lake City, Utah, United States, 84102
United States, Washington
1951 152nd Place NE
Bellevue, Washington, United States, 98007
601 Broadway
Seattle, Washington, United States, 98122
Sponsors and Collaborators
Tonix Pharmaceuticals, Inc.
Study Director: Mark R. Schmal Premier Research Group plc
Study Chair: Daniel J. Clauw, MD Ann Harbor, MI
  More Information

Responsible Party: Tonix Pharmaceuticals, Inc. Identifier: NCT01903265     History of Changes
Other Study ID Numbers: TNX-CY-F202 
Study First Received: July 12, 2013
Last Updated: November 5, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by Tonix Pharmaceuticals, Inc.:

Additional relevant MeSH terms:
Myofascial Pain Syndromes
Muscular Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Neuromuscular Diseases
Nervous System Diseases
Antidepressive Agents, Tricyclic
Antidepressive Agents
Psychotropic Drugs
Muscle Relaxants, Central
Physiological Effects of Drugs
Neuromuscular Agents
Peripheral Nervous System Agents
Tranquilizing Agents
Central Nervous System Depressants processed this record on December 06, 2016